Table 1.

Patient demographics, characteristics, and cytogenetics of pediatric AML PDX lines.

Sample	Ethnicity	Age (Years)/Sex	AML Sub Type	Sample Collected at	FISH	Karyotype	Genomics (Archer Panel)
NTPL-60	African American	4/M	M7	Diagnosis	Trisomy 21, AML1 and ETO amplification	46, XY der (14;21) (q10;q10), +21c [cp12]/48, idem, +8, +der (14;21) (q10; q10) [cp8}−	GATA1 mutation
NTPL-377	Hispanic	1.5/F	M5	Diagnosis	KMT2A rearrangement	46, XX, t(9;11)(p21;q23)[20]	KMT2A-MLLT3 (56%)
NTPL-386	Non-Hispanic	2/M	M7	Diagnosis	Trisomy 21, RUNX1 amplification	47,XY,del(13)(q12q14),+21c [12]/47,ldem,l(7)(q10)[3]/47,XY,+21c[5]	GATA1 mutation; KMT2A-TMEM25 (8%)
NTPL-511	Unknown	14/M	M2	Diagnosis	Negative	47, XY,+8[1]/46,XY[29]	NUP98-NSD1 (20%); NSD1-NUP98 (7%)
NTPL-662	Unknown	14/M	M7	Diagnosis	Trisomy 21, low level trisomy 8	47, XY,+21c[91]/48,idem,+8[2]	none
DF-2 (CBAM-68552)	Caucasian	1/M	M5	Relapse following chemotherapy	KMT2A rearrangement	46,XY,inv(6)(q23q27)[20]	KMT2A-MLLT4 (54%)
NTPL-257	Caucasian	3/F		Normal
NTPL-793	Caucasian	13/F		Normal
NTPL-827	African American	0.6/M		Normal
NTPL-837	African American	2/M		Normal